Underutilization of gene expression profiling for early-stage breast cancer in California

Cancer Causes and Control

Volumn 27, Issue 6, 2016, Pages 721-727

  Cress, Rosemary D ^a,b   Chen, Yingjia S ^a   Morris, Cyllene R ^c   Chew, Helen ^d   Kizer, Kenneth W ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PUBLIC HEALTH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Cancer registry; Chemotherapy; Gene expression profiling; Genomics

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASIAN; BLACK PERSON; BREAST CANCER; CALIFORNIA; CANCER ADJUVANT THERAPY; CANCER STAGING; CAUCASIAN; DISEASE ASSOCIATION; EARLY CANCER; ETHNICITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MIDDLE AGED; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; AFRICAN AMERICAN; AGE; ASIAN AMERICAN; BREAST NEOPLASMS; ETHNOLOGY; GENETICS; HEALTH CARE DISPARITY; MASTECTOMY; PATHOLOGY; REGISTER; RISK; SOCIAL CLASS; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE; UNITED STATES; UTILIZATION;

AFRICAN AMERICANS; AGE FACTORS; AGED; ASIAN AMERICANS; BREAST NEOPLASMS; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION PROFILING; HEALTHCARE DISPARITIES; HUMANS; MASTECTOMY; MEDICAID; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REGISTRIES; RISK; SOCIAL CLASS; UNITED STATES;

EID: 84964330552     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-016-0743-4     Document Type: Article

References (23)

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
2. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734
3. Haas JS, Liang SY, Hassett MJ, Shiboski S, Elkin EB, Phillips KA (2011) Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat 130:619–626
4. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical O (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312
5. Lyman GH, Cosler LE, Kuderer NM, Hornberger J (2007) Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109:1011–1018
6. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677–1683
7. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R, Invasive Breast Cancer Version 1 (2016) NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 14:324–354
8. Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711
9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826
10. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K, Early Breast Cancer Trialists’ Collaborative G (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444
11. Enewold L, Geiger AM, Zujewski J, Harlan LC (2015) Oncotype DX assay and breast cancer in the United States: usage and concordance with chemotherapy. Breast Cancer Res Treat 151:149–156
12. Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH (2015) Association between use of the 21-gene recurrence score assay and receipt of chemotherapy among Medicare beneficiaries with early-stage breast cancer, 2005–2009. JAMA Oncol 1:1098–1109
13. Nguyen MT, Stessin A, Nagar H, D’Alfonso TM, Chen Z, Cigler T, Hayes MK, Shin SJ (2014) Impact of oncotype DX recurrence score in the management of breast cancer cases. Clin Breast Cancer 14:182–190
14. Guth AA, Fineberg S, Fei K, Franco R, Bickell NA (2013) Utilization of oncotype DX in an inner city population: race or place? Int J Breast Cancer 2013:653805
15. Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC (2012) Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 30:2218–2226
16. Griggs JJ, Hawley ST, Graff JJ, Hamilton AS, Jagsi R, Janz NK, Mujahid MS, Friese CR, Salem B, Abrahamse PH, Katz SJ (2012) Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol 30:3058–3064
17. Warren JL, Butler EN, Stevens J, Lathan CS, Noone AM, Ward KC, Harlan LC (2014) Receipt of chemotherapy among Medicare patients with cancer by type of supplemental insurance. J Clin Oncol 33:312–318
18. Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB (2016) Racial variation in the uptake of oncotype DX testing for early-stage breast cancer. J Clin Oncol 34:130–138
19. Carlson JJ, Roth JA (2013) The impact of the Oncotype DX breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 141:13–22
20. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721–728
21. Potosky AL, O’Neill SC, Isaacs C, Tsai HT, Chao C, Liu C, Ekezue BF, Selvam N, Kessler LG, Zhou Y, Schwartz MD (2015) Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. Cancer 121:4062–4070
22. Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL (2014) Comparison of SEER treatment data with medicare claims. Med Care. doi:10.1097/MLR.0000000000000073
23. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Jr., Dees EC, Perez EA, Olson JA, Jr., Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014